APOE4驱动肝脏蛋白质组的广泛变化,并改变代谢功能
Colton R Lysaker1,2, Chelsea N Johnson2,3, Vivien Csikos1,2
1Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA.
bioRxiv : the preprint server for biology
|July 16, 2025
概括
阿波利波蛋白E4 (APOE4) 基因变体显著损害肝脏线粒体功能,并以性别特定的方式重新连接肝脏新陈代谢,影响葡萄糖和脂质处理.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 遗传学 是一个遗传学.
背景情况:
- 脂蛋白E (APOE) 对于脂质稳定至关重要,APOE4等位基因与阿尔茨海默病风险增加和代谢功能障碍有关.
- 虽然APOE在大脑中的作用得到了充分研究,但由于遗传变异,它对肝脏健康和新陈代谢的影响不明.
研究的目的:
- 研究APOE3和APOE4遗传变异对肝脏健康和新陈代谢的影响.
- 检查APOE对肝功能影响的性别特异性差异.
- 利用小鼠模型和人类相关的iPSC衍生细胞来阐明APOE的肝脏机制.
主要方法:
- 使用年轻的雌性和雄性APOE3和APOE4向替代小鼠.
- 使用的APOE是异位诱导的多能干细胞 (iPSC) 衍生的肝细胞样细胞 (iHLC).
- 进行蛋白质和功能测试以评估线粒体功能,葡萄糖和脂质代谢以及基因表达.
主要成果:
- 在小鼠中,APOE4以性别特定的方式显著改变了肝脏线粒体功能.
- 在人类的iHLC中,APOE4损害了线粒体功能,促进了糖解,改变了细胞外基质蛋白的表达.
- APOE4 iHLCs 显示对脂肪酸的能量依赖性增加,脂质积累更大.
结论:
- APOE遗传变异,特别是APOE4,诱导肝脏中的线粒体功能障碍.
- APOE4重新连接肝脏新陈代谢,转向糖解和增加脂质积累.
- 这些发现突出了性别特异性的影响,并为APOE对肝脏的影响提供了与人类相关的细胞模型.
相关概念视频
Drug Metabolism: Phase I Reactions
3.7K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.7K
Hepatic Drug Excretion: Influencing Factors
229
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
229
Liver Physiology
1.3K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
1.3K
Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
Regulation of Metabolism
9.9K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.9K
Hepatic Drug Clearance: Effect of Protein Binding
288
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
288


